Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants (ADACAL)

3 maja 2016 zaktualizowane przez: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

cAlprotectin and hsCRP as Markers of a New Diagnostic-therapeutic strAtegy That Assesses muCosal Activity to individuaLize Treatment and Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants

This study will test that individualized treatment in patients with Crohn's Disease in remission or mild clinical activity under immunosuppressants may improve prognosis, rather than just treating flares.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

Patients will be prescreened for inclusion criteria one week before the start of screening at Visit 0 (Prescreening Visit). Patients must be on stable doses of azathioprine/mercaptopurine. Patients will be given a diary to record their CD symptoms for the seven days prior to Visit 1. At Visit 1 (Screening Visit 1), patients will have their CDAI score assessed based upon their diary information. Patients with CDAI ≤ 220 will then have both calprotectin and hsCRP testing done. Patients with calprotectin > or = 250µg/g and/or hsCRP > or = 5mg/L will be notified and told to schedule Visit 2 within three weeks. At Visit 2 (Screening Visit 2), patients will undergo a colonoscopy. A Crohn's Disease Endoscopic Index of Severity (CDEIS) will be used to determine the endoscopic activity. Patients with significant endoscopic lesions will be notified and asked to enroll in the study.

Patients will be randomized into the study at Visit 3 (Randomization Visit, same day of Visit 2 in results available). Due to the cost and invasiveness of the colonoscopy, the Screening Visit 2 colonoscopy will serve as the baseline for the study, should the patient be enrolled. Drug will also be dispensed at this visit. Eligible patients will be randomized in a 1:1 ratio to receive either adalimumab or placebo during the treatment period, along with continuing their current immunosuppressive maintenance treatment at a stable dose. Treatment in both arms will be induction at 160/80mg and maintenance on 40 mg every other week.

Patients will return for follow up visits every 12 weeks until the final follow-up visit at 48 weeks (Visit 7), where another colonoscopy will be performed. Patients who terminate early from the study for any reason will be asked to return for a follow-up visit, where Visit 7 procedures will be performed.

Before week 48, if a patient has an increase of more than 50% in either calprotectin and/or hsCRP over baseline and above the thresholds at any regular visit, a follow-up visit will be performed two weeks later. If the 50% increase is still observed another colonoscopy will be performed, within two weeks of the follow-up visit. If patients still have significant endoscopic lesions, study product will be intensified to 40 mg weekly. This will include patients on placebo in order to preserve the double-blind aspect of the study.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

15

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Belgia
      • Bonheiden, Belgia, 2820
        • Imeldaziekenhuis Bonheiden
      • Bruxelles, Belgia, 1070
        • Hospital Erasme Bruxelles
      • Bruxelles, Belgia, 1200
        • Hospital Saint Luc Bruxelles
      • Gent, Belgia, 9000
        • Hospital University Gent
      • Liege, Belgia, 4000
        • Centre Hospitalier Universitaire de Liege
      • Roeselare, Belgia, 8800
        • Heiling Hartzieknhuis Roeselare
  • Francja
      • Amiens, Francja, 80054
        • CHU Amiens - Hospital Nord
      • Clichy, Francja, 92110
        • Hospital Beaujon
      • Lille, Francja, 59037
        • CHRU Lille - Hospital Claude Huriez
      • Lyon, Francja, 69495
        • CHU Lyon Sud
      • Nantes, Francja, 44093
        • CHU Nantes
      • Paris, Francja, 75010
        • Hospital Saint Louis
      • Reims, Francja, 51092
        • CHRU Reims - Hospital Robert Debre
      • Rouen, Francja, 76031
        • CHU Rouen - Hospital Charles Nicolle
      • Saint Etienne, Francja, 42270
        • CH Saint Etienne - Hospital Nord
    • Bordeaux
      • Pessac, Bordeaux, Francja, 33604
        • CHU Bordeaux - Hospital Haut-Leveque
    • Nancy
      • Vandoeuvre Les Nancy, Nancy, Francja, 54500
        • CHU Nancy - Hospital de Brabois Adultes
    • Tours
      • Chambray, Tours, Francja, 76031
        • CHU TOURS - Hospital Trousseau
  • Hiszpania
      • Barcelona, Hiszpania, 08025
        • Hospital Santa Creu i Sant Pau
      • Madrid, Hiszpania, 28034
        • Hospital Ramon y Cajal
      • Madrid, Hiszpania, 28007
        • Hospital Gregorio Marañón
      • Madrid, Hiszpania, 28005
        • Hospital Universitario La Princesa
      • Sevilla, Hiszpania, 41013
        • Hospital Virgen Del Rocio
      • Valencia, Hiszpania, 46010
        • Hospital Clínico de Valencia
      • Zaragoza, Hiszpania
        • Hospital Lozano Blesa
    • A coruña
      • Santiago de Compostela, A coruña, Hiszpania
        • Complejo Hospitalario Santiago de Compostela
    • Andalucía
      • Córdoba, Andalucía, Hiszpania, 14004
        • Hospital Universitario Reina Sofia
    • Barcelona
      • Badalona, Barcelona, Hiszpania
        • Hospital Germans Trías i Pujol
    • Canarias
      • Las Palmas de Gran Canarias, Canarias, Hiszpania, 35010
        • Hospital Doctor Negrín
    • Valencia
      • Manises, Valencia, Hiszpania, 46940
        • Hospital de Manises

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 75 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Age 18-75 years old- Patients with CD diagnosis confirmed by colonoscopy
  • Patients with inflammatory CD of terminal ileal, colonic or ileocolonic location
  • Maintenance treatment with at least 2 mg/kg/day for azathioprine/ 1 mg/kg/day for mercaptopurine or the highest dosage tolerated in patients who could not tolerate this dosage, at least 6 months.
  • Willingness to sign informed consent
  • If female of childbearing age, be post-menopausal, surgically sterile, or willing to use a reliable form of birth control for the duration of the study (such as physical barrier [patient and partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device)and for at least five months after the last adalimumab treatment.
  • Able to comply with the requirements of the study.
  • CDAI score ≤ 220.
  • Calprotectin > or = 250µg/g and/or hsCRP > or = 5mg/L.
  • Significant lesions seen during colonoscopy, as defined by CDEIS.

Exclusion Criteria:

  • Patients with an ostomy, or ileoanal pouch (subject with previous ileo-rectal anastomosis are not excluded), draining fistula, abscess
  • Patients who had intestinal resection within one year.
  • Symptomatic stricture either diagnosed by colonoscopy or clinically suspected and confirmed by imaging techniques.
  • Prior treatment with any anti-tumor necrosis factor (TNF) drug.
  • Patients receiving rectal treatment 1 month before inclusion
  • Signs of active infection
  • Previous history of active untreated or inadequately treated tuberculosis (TB) or latent TB. Patients should be screened for latent TB as per local guidelines or clinical practice in the country of study conduct. Patients with latent TB should be treated with standard antimycobacterial therapy (for at least 4 weeks) before initiating biologic therapy and have a negative CRX for active TB at screening
  • Subjects with a poorly controlled medical condition such as: uncontrolled diabetes with documented history of recurrent infections, unstable ischemic heart disease, moderate to severe congestive heart failure (New York Heart Association [NYHA] class III or IV), recent cerebrovascular accident, or any other condition which, in the opinion of the Investigator or the sponsor, would put the subject at risk by participation in the protocol
  • Signs of colon cancer or dysplasia
  • Signs of severe or unstable renal, hepatic, gastrointestinal, cardiovascular, respiratory, neurological, psychiatric, or hematological disease
  • Signs of cancer in the past five years, except for localized and treated basal cell skin cancer or cervical cancer
  • Patients who are pregnant or nursing

  • Concomitant treatment with:

    • Live vaccines.
    • 5-ASA compounds: Rectal 5-ASA should be discontinued at least 4 weeks before study inclusion. Oral 5-ASA must be at a stable dose for at least 4 weeks before study inclusion. If oral 5-ASA has recently been discontinued, 4 weeks should pass before study inclusion.
    • Oral corticosteroids (eg., Prednisone, budesonide) should be discontinued for 3 months before study inclusion.
    • Antibiotics for CD. Only antibiotics used to treat a concurrent infection are allowed.
    • Immunomodulators:

Patients receiving therapy with azathioprine/mercaptopurine must have been on a stable dose for at least 12 weeks before inclusion and must continue with the same dose during the study.

No treatment with other known immunomodulators (eg. methotrexate, 6-thioguanine [6-TG], cyclosporine, tacrolimus, sirolimus, ustekinumab, pentoxifylline, or mycophenolate mofetil) or experimental drugs (eg., factor colony stimulating granulocyte macrophage [GM-CSF]) within 6 months

  • Monoclonal antibodies or anti-TNF drugs.

  • Aspirin or Non-steroidal anti-inflammatory drugs (NSAIDs). Treatment with aspirin and/or NSAIDS should not occur for more than 15 consecutive days before collecting of the stool sample for Calprotectin and performing the colonoscopy.

    - Screening laboratory and other analyses show any of the following abnormal results:

  • Aspartate transaminase (AST) or alanine transaminase (ALT) > 2 x the upper limit of the reference range;
  • Total bilirubin ≥ 3 mg/dL (51 μmol/L);

  • Serum creatinine > 1.6 mg/dL (144 μmol/L)

    • History of any drug or alcohol abuse in the past 2 years
    • Receipt of other study product within 3 months of inclusion in this study
    • Patients employed by the sponsor or in any relationship of dependence with the sponsor and/or investigator
    • Staff at the study center
    • Hypersensitivity to the active substance or to any of the excipients

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Komparator placebo: PLACEBO
Treatment with placebo
Lek: Placebo
PLACEBO at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly
Aktywny komparator: ADALIMUMAB
Treatment with Adalimumab
Lek: ADALIMUMAB
Adalimumab at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly.
Inne nazwy:
  • HUMIRA

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
The primary efficacy endpoint is the rate of therapeutic failure up to week 48
Ramy czasowe: Every 12 weeks up to Week 48

The therapeutic failure is defined as any of following cases:

  1. CDAI > 220 with at least 70-point increase from baseline over two consecutive visits 12 weeks apart or CDAI > 300 at any time point during the study;
  2. need of any change in therapy for CD except the ones planned per protocol in each group of the study;
  3. need of surgery related to CD or of stricture endoscopic dilatation.
Every 12 weeks up to Week 48

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
The rate of therapeutic failure (see the definition of primary endpoint) up to week 24
Ramy czasowe: up to week 24
up to week 24
Change in CDEIS from baseline to week 48
Ramy czasowe: up to week 48
CDEIS = Crohn's Disease Endoscopic Index of Severity.
up to week 48
The rate of mucosal healing (CDEIS=0) at week 48
Ramy czasowe: at week 48
CDEIS = Crohn's Disease Endoscopic Index of Severity
at week 48
The rate of CDEIS remission (CDEIS<=3) at week 48
Ramy czasowe: at week 48
CDEIS = Crohn's Disease Endoscopic Index of Severity
at week 48
The rate of CDEIS response, which is defined as a decrease of at least 4 points in CDEIS from baseline to week 48
Ramy czasowe: from baseline up to week 48
CDEIS = Crohn's Disease Endoscopic Index of Severity
from baseline up to week 48
Change in CDAI from baseline to week 12, 24, 36 and 48
Ramy czasowe: from baseline to week 12, 24, 36 and 48
CDAI = Crohn's Disease Activity Index.
from baseline to week 12, 24, 36 and 48
Change in the global score based on IBDQ from baseline to week 12, 24, 36, and 48.
Ramy czasowe: from baseline to week 12, 24, 36, and 48.
IBDQ = Inflammatory Bowel Disease Questionnaire.
from baseline to week 12, 24, 36, and 48.
Area Under the Curve (AUC) over 48 weeks for CDAI
Ramy czasowe: 48 weeks
48 weeks
The number of surgical interventions related to CD up to 24 and 48 weeks
Ramy czasowe: up to 24 and 48 weeks
up to 24 and 48 weeks
The rate of hospital admissions related to the disease, to the treatment side effects or other causes up to weeks 24 or 48
Ramy czasowe: up to weeks 24 or 48
up to weeks 24 or 48
The rate of serious AEs between the two strategies up to 24 and 48 weeks
Ramy czasowe: up to 24 and 48 weeks
up to 24 and 48 weeks
The rate of serious AEs requiring the cessation of the ongoing treatment between the two strategies up to 24 and 48 weeks.
Ramy czasowe: up to 24 and 48 weeks
up to 24 and 48 weeks
The accuracy of calprotectin/hsCRP to predict therapeutic failure 12 weeks in advance
Ramy czasowe: 12 weeks
12 weeks
The correlation between calprotectin, hsCRP and CDAI at any time points during the study.
Ramy czasowe: 48 weeks
Pearson Product-Moment Correlation will be used to evaluate correlations between calprotectin, hsCRP and CDAI at all scheduled visits.
48 weeks
The correlation between calprotectin/hsCRP and CDEIS or mucosal healing at Baseline and Week 48.
Ramy czasowe: at Baseline and Week 48.
Pearson Product-Moment Correlation will also be used to evaluate between calprotectin (and hsCRP) and CDEIS at Baseline and Week 48.
at Baseline and Week 48.
Change in the scores based on WPAI from baseline to week 12, 24, 36 and 48
Ramy czasowe: from baseline to week 12, 24, 36 and 48
WPAI = Work Productivity and Activity Impairment Questionnaire
from baseline to week 12, 24, 36 and 48
The change in calprotectin and hsCRP from baseline to week 12, 24, 36, and 48
Ramy czasowe: from baseline to week 12, 24, 36, and 48
from baseline to week 12, 24, 36, and 48

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

Współpracownicy

Abbott
TFS Trial Form Support

Śledczy

  • Główny śledczy: VALLE GARCÍA, MD, Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 października 2012

Zakończenie podstawowe (Rzeczywisty)

1 marca 2014

Ukończenie studiów (Rzeczywisty)

1 marca 2014

Daty rejestracji na studia

Pierwszy przesłany

13 marca 2012

Pierwszy przesłany, który spełnia kryteria kontroli jakości

22 marca 2012

Pierwszy wysłany (Oszacować)

26 marca 2012

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Oszacować)

4 maja 2016

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

3 maja 2016

Ostatnia weryfikacja

1 maja 2016

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • A12-771

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj